

July 30, 2020
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis

TOKYO, Japan, July 30, 2020 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced that its U.S. licensor of rigosertib, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova"), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), announced on July 29, 2020 (EST) that the required number of survival events for the pivotal Phase 3 INSPIRE has been reached. Onconova anticipates announcing topline data by the end of the third quarter of 2020.

According to Onconova's press release, Onconova plans to disclose the initial topline data results when available, via press release and subsequent conference call, with a full data presentation anticipated at a major medical conference later this year.

For Onconova's full press release, please visit Onconova's website:

<https://investor.onconova.com/press-releases>

The Company does not expect the information presented herein to have any material impact on its financial outlook for the fiscal year ending December 2020.

About Rigosertib

Rigosertib is a small molecule inhibitor that has a new mechanism of action: it inhibits the activation of RAS as an oncogene-related product, thereby blocking the action of multikinases, including PI3K, and inhibits cellular signaling in cancer cells necessary for their survival and proliferation, thus killing cancer cells. SymBio obtained the development and commercialization licensing rights for Rigosertib from Onconova in July 2011 for Japan and Korea.

About Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel drugs to treat cancer, with an initial focus on myelodysplastic syndromes (MDS). Onconova has a pipeline of proprietary targeted agents designed to work against specific cellular pathways that are important in cancer cells. For more information, please visit <https://www.onconova.com>.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, the Company incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.